Share Price and Basic Stock Data
Last Updated: October 17, 2025, 9:01 pm
| PEG Ratio | -38.62 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Healthcare Global Enterprises Ltd (HCG) operates in the Hospitals & Medical Services sector and has shown a consistent upward trajectory in revenue. For the fiscal year ending March 2025, HCG reported sales of ₹2,223 Cr, a significant increase from ₹1,691 Cr in March 2023. This represents a growth of approximately 31.4% year-on-year. Quarterly sales also demonstrated a robust trend, with the latest recorded sales at ₹494.63 Cr in March 2024, up from ₹441.71 Cr in March 2023. The company’s operational performance is reflected in its operating profit margin (OPM), which stood at 17% for the fiscal year 2025, indicating a stable margin in a competitive healthcare landscape. Moreover, the company has managed to enhance its operational efficiency, as evidenced by a cash conversion cycle of -111 days, suggesting effective management of receivables and payables. Overall, HCG’s revenue trends are promising, positioning the company favorably within the industry.
Profitability and Efficiency Metrics
HCG’s profitability metrics indicate a mixed performance, with net profit recorded at ₹49 Cr for the fiscal year 2025, up from ₹18 Cr in the previous year. However, the company’s price-to-earnings (P/E) ratio is notably high at 264, which may raise concerns about valuation in comparison to industry peers. The return on equity (ROE) for the company stood at 5.14%, while return on capital employed (ROCE) was slightly better at 8.56%. These figures suggest that while HCG is generating profits, the returns relative to equity and capital employed might not be as competitive. The interest coverage ratio (ICR) of 3.19x indicates that HCG is comfortably able to service its debt obligations, a positive sign for investors. However, the OPM of 17% reflects a need for improved cost management, particularly as expenses rose to ₹1,836 Cr in the same fiscal year.
Balance Sheet Strength and Financial Ratios
HCG’s balance sheet shows a total borrowing of ₹1,837 Cr against reserves of ₹783 Cr, highlighting a debt-to-equity ratio of 0.81. This indicates a moderate level of leverage, which could be a risk factor if the company does not manage its debt effectively. The current and quick ratios stand at 0.91x and 0.85x, respectively, suggesting liquidity concerns, as values below 1 indicate potential challenges in meeting short-term liabilities. Additionally, the company’s book value per share decreased slightly to ₹59.28 in March 2024 from ₹61.86 in the previous year, which may reflect a dilution of shareholder value due to high borrowings. However, the company’s total assets rose to ₹3,540 Cr, which bodes well for its operational capabilities. Overall, while HCG maintains a reasonable asset base, its reliance on debt and liquidity ratios warrant close monitoring.
Shareholding Pattern and Investor Confidence
The shareholding structure of HCG shows a significant concentration among promoters, who hold 62.46% of the shares, down from 71.39% in September 2022. This reduction may indicate a strategic move to increase liquidity or attract institutional investors. Foreign Institutional Investors (FIIs) hold 2.16%, while Domestic Institutional Investors (DIIs) increased their stake to 13.22%. The public shareholding has risen to 22.17%, suggesting growing interest from retail investors. Despite the decline in promoter holding, the increase in public and DII stakes reflects confidence in the company’s growth potential. The total number of shareholders has also risen to 47,028, indicating a broadened investor base. This diversification can be beneficial for HCG as it seeks to enhance its market presence and mitigate risks associated with concentrated ownership.
Outlook, Risks, and Final Insight
If HCG manages to sustain its revenue growth and improve operational efficiency, it could enhance profitability metrics and investor confidence. However, the high P/E ratio raises questions about valuation sustainability in a competitive market. Risks include the company’s reliance on debt, as indicated by its debt-to-equity ratio and liquidity issues highlighted by current ratios below 1. Furthermore, the volatility in net profits, particularly with fluctuations in tax rates impacting earnings, poses a challenge. If margins can be improved through better cost management and operational efficiencies are maintained, HCG may strengthen its position in the healthcare sector. The evolving shareholding pattern also suggests potential shifts in investor sentiment, which could further influence the company’s strategic direction moving forward.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Healthcare Global Enterprises Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 47.5 Cr. | 142 | 195/140 | 6.38 | 115 | 2.47 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 26.2 Cr. | 25.0 | 37.6/0.00 | 25.5 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 14.1 Cr. | 13.7 | 23.4/12.1 | 157 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 125 Cr. | 66.9 | 98.7/51.0 | 27.2 | 16.1 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 23.8 Cr. | 4.40 | 7.73/3.40 | 0.80 | 2.49 | 0.00 % | 79.2 % | 85.5 % | 10.0 |
| Industry Average | 29,596.57 Cr | 861.27 | 67.57 | 94.89 | 0.31% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 408.05 | 420.00 | 424.68 | 441.71 | 460.68 | 486.94 | 469.87 | 494.63 | 525.58 | 553.54 | 558.57 | 585.16 | 613.16 |
| Expenses | 335.89 | 345.31 | 349.18 | 365.40 | 386.37 | 402.32 | 391.26 | 402.60 | 434.68 | 451.30 | 470.19 | 479.53 | 505.37 |
| Operating Profit | 72.16 | 74.69 | 75.50 | 76.31 | 74.31 | 84.62 | 78.61 | 92.03 | 90.90 | 102.24 | 88.38 | 105.63 | 107.79 |
| OPM % | 17.68% | 17.78% | 17.78% | 17.28% | 16.13% | 17.38% | 16.73% | 18.61% | 17.30% | 18.47% | 15.82% | 18.05% | 17.58% |
| Other Income | 2.91 | 1.97 | 3.65 | 4.65 | 2.77 | 3.40 | 6.07 | 9.01 | 8.81 | 11.13 | 5.54 | 10.23 | 7.51 |
| Interest | 24.98 | 25.81 | 27.08 | 25.63 | 25.55 | 26.89 | 29.46 | 26.84 | 33.71 | 35.98 | 40.70 | 44.17 | 45.47 |
| Depreciation | 39.67 | 40.83 | 40.77 | 42.20 | 41.01 | 43.21 | 44.16 | 45.98 | 47.01 | 49.74 | 56.52 | 58.07 | 57.91 |
| Profit before tax | 10.42 | 10.02 | 11.30 | 13.13 | 10.52 | 17.92 | 11.06 | 28.22 | 18.99 | 27.65 | -3.30 | 13.62 | 11.92 |
| Tax % | 76.20% | 47.21% | 62.83% | 56.97% | 65.30% | 39.84% | 68.99% | 16.87% | 28.23% | 25.21% | -334.85% | 50.29% | 49.83% |
| Net Profit | 2.48 | 5.29 | 4.20 | 5.65 | 3.65 | 10.78 | 3.43 | 23.46 | 13.63 | 20.68 | 7.75 | 6.77 | 5.98 |
| EPS in Rs | 0.44 | 0.53 | 0.54 | 0.60 | 0.55 | 0.97 | 0.41 | 1.53 | 0.87 | 1.29 | 0.50 | 0.53 | 0.34 |
Last Updated: August 1, 2025, 8:20 pm
Below is a detailed analysis of the quarterly data for Healthcare Global Enterprises Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 613.16 Cr.. The value appears strong and on an upward trend. It has increased from 585.16 Cr. (Mar 2025) to 613.16 Cr., marking an increase of 28.00 Cr..
- For Expenses, as of Jun 2025, the value is 505.37 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 479.53 Cr. (Mar 2025) to 505.37 Cr., marking an increase of 25.84 Cr..
- For Operating Profit, as of Jun 2025, the value is 107.79 Cr.. The value appears strong and on an upward trend. It has increased from 105.63 Cr. (Mar 2025) to 107.79 Cr., marking an increase of 2.16 Cr..
- For OPM %, as of Jun 2025, the value is 17.58%. The value appears to be declining and may need further review. It has decreased from 18.05% (Mar 2025) to 17.58%, marking a decrease of 0.47%.
- For Other Income, as of Jun 2025, the value is 7.51 Cr.. The value appears to be declining and may need further review. It has decreased from 10.23 Cr. (Mar 2025) to 7.51 Cr., marking a decrease of 2.72 Cr..
- For Interest, as of Jun 2025, the value is 45.47 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 44.17 Cr. (Mar 2025) to 45.47 Cr., marking an increase of 1.30 Cr..
- For Depreciation, as of Jun 2025, the value is 57.91 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 58.07 Cr. (Mar 2025) to 57.91 Cr., marking a decrease of 0.16 Cr..
- For Profit before tax, as of Jun 2025, the value is 11.92 Cr.. The value appears to be declining and may need further review. It has decreased from 13.62 Cr. (Mar 2025) to 11.92 Cr., marking a decrease of 1.70 Cr..
- For Tax %, as of Jun 2025, the value is 49.83%. The value appears to be improving (decreasing) as expected. It has decreased from 50.29% (Mar 2025) to 49.83%, marking a decrease of 0.46%.
- For Net Profit, as of Jun 2025, the value is 5.98 Cr.. The value appears to be declining and may need further review. It has decreased from 6.77 Cr. (Mar 2025) to 5.98 Cr., marking a decrease of 0.79 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.34. The value appears to be declining and may need further review. It has decreased from 0.53 (Mar 2025) to 0.34, marking a decrease of 0.19.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:13 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 451 | 519 | 584 | 700 | 829 | 976 | 1,092 | 1,009 | 1,395 | 1,691 | 1,908 | 2,218 | 2,310 |
| Expenses | 413 | 443 | 499 | 595 | 713 | 864 | 936 | 887 | 1,161 | 1,394 | 1,581 | 1,835 | 1,906 |
| Operating Profit | 38 | 76 | 85 | 105 | 116 | 112 | 157 | 122 | 234 | 297 | 327 | 384 | 404 |
| OPM % | 9% | 15% | 15% | 15% | 14% | 11% | 14% | 12% | 17% | 18% | 17% | 17% | 17% |
| Other Income | 3 | 0 | -2 | 10 | 25 | 10 | 10 | -72 | 110 | 15 | 24 | 39 | 34 |
| Interest | 32 | 34 | 38 | 23 | 42 | 70 | 138 | 119 | 98 | 104 | 109 | 155 | 166 |
| Depreciation | 36 | 39 | 44 | 57 | 71 | 85 | 148 | 159 | 158 | 163 | 174 | 211 | 222 |
| Profit before tax | -27 | 3 | 0 | 35 | 27 | -33 | -119 | -229 | 88 | 45 | 68 | 57 | 50 |
| Tax % | 20% | -56% | -730% | 34% | 38% | -7% | 5% | -3% | 56% | 61% | 39% | 14% | |
| Net Profit | -32 | 5 | 2 | 23 | 17 | -31 | -125 | -221 | 39 | 18 | 41 | 49 | 41 |
| EPS in Rs | -5.21 | 0.12 | -0.17 | 2.59 | 2.36 | -2.82 | -12.03 | -15.43 | 3.87 | 2.11 | 3.46 | 3.19 | 2.66 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 115.62% | -60.00% | 1050.00% | -26.09% | -282.35% | -303.23% | -76.80% | 117.65% | -53.85% | 127.78% | 19.51% |
| Change in YoY Net Profit Growth (%) | 0.00% | -175.62% | 1110.00% | -1076.09% | -256.27% | -20.87% | 226.43% | 194.45% | -171.49% | 181.62% | -108.27% |
Healthcare Global Enterprises Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 15% |
| 3 Years: | 17% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 52% |
| 5 Years: | 19% |
| 3 Years: | 73% |
| TTM: | -26% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 42% |
| 3 Years: | 37% |
| 1 Year: | 70% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 0% |
| 3 Years: | 5% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 5:55 am
Balance Sheet
Last Updated: October 10, 2025, 2:09 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 68 | 70 | 85 | 86 | 87 | 88 | 89 | 125 | 139 | 139 | 139 | 139 |
| Reserves | 196 | 210 | 341 | 347 | 428 | 389 | 293 | 572 | 731 | 721 | 686 | 783 |
| Borrowings | 292 | 349 | 324 | 420 | 464 | 658 | 1,347 | 977 | 915 | 901 | 1,274 | 1,837 |
| Other Liabilities | 133 | 147 | 294 | 372 | 461 | 515 | 518 | 357 | 433 | 549 | 601 | 780 |
| Total Liabilities | 688 | 776 | 1,043 | 1,225 | 1,440 | 1,650 | 2,246 | 2,031 | 2,218 | 2,311 | 2,701 | 3,540 |
| Fixed Assets | 512 | 528 | 583 | 685 | 828 | 970 | 1,646 | 1,382 | 1,547 | 1,553 | 1,758 | 2,442 |
| CWIP | 11 | 42 | 121 | 148 | 174 | 153 | 46 | 30 | 22 | 18 | 83 | 25 |
| Investments | 2 | 0 | 64 | 11 | 53 | 49 | 34 | 26 | 9 | 10 | 10 | 11 |
| Other Assets | 164 | 205 | 275 | 381 | 385 | 478 | 520 | 593 | 641 | 730 | 850 | 1,062 |
| Total Assets | 688 | 776 | 1,043 | 1,225 | 1,440 | 1,650 | 2,246 | 2,031 | 2,218 | 2,311 | 2,701 | 3,540 |
Below is a detailed analysis of the balance sheet data for Healthcare Global Enterprises Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 139.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 139.00 Cr..
- For Reserves, as of Mar 2025, the value is 783.00 Cr.. The value appears strong and on an upward trend. It has increased from 686.00 Cr. (Mar 2024) to 783.00 Cr., marking an increase of 97.00 Cr..
- For Borrowings, as of Mar 2025, the value is 1,837.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 1,274.00 Cr. (Mar 2024) to 1,837.00 Cr., marking an increase of 563.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 780.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 601.00 Cr. (Mar 2024) to 780.00 Cr., marking an increase of 179.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 3,540.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,701.00 Cr. (Mar 2024) to 3,540.00 Cr., marking an increase of 839.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 2,442.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,758.00 Cr. (Mar 2024) to 2,442.00 Cr., marking an increase of 684.00 Cr..
- For CWIP, as of Mar 2025, the value is 25.00 Cr.. The value appears to be declining and may need further review. It has decreased from 83.00 Cr. (Mar 2024) to 25.00 Cr., marking a decrease of 58.00 Cr..
- For Investments, as of Mar 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Mar 2024) to 11.00 Cr., marking an increase of 1.00 Cr..
- For Other Assets, as of Mar 2025, the value is 1,062.00 Cr.. The value appears strong and on an upward trend. It has increased from 850.00 Cr. (Mar 2024) to 1,062.00 Cr., marking an increase of 212.00 Cr..
- For Total Assets, as of Mar 2025, the value is 3,540.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,701.00 Cr. (Mar 2024) to 3,540.00 Cr., marking an increase of 839.00 Cr..
However, the Borrowings (1,837.00 Cr.) are higher than the Reserves (783.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -254.00 | -273.00 | -239.00 | -315.00 | -348.00 | -546.00 | 156.00 | -855.00 | -681.00 | -604.00 | 326.00 | 383.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 43 | 45 | 43 | 54 | 57 | 59 | 62 | 67 | 57 | 65 | 56 | 66 |
| Inventory Days | 33 | 36 | 32 | 40 | 46 | 45 | 35 | 32 | 31 | 33 | 33 | 33 |
| Days Payable | 193 | 208 | 264 | 272 | 274 | 303 | 234 | 221 | 199 | 214 | 216 | 210 |
| Cash Conversion Cycle | -117 | -127 | -188 | -178 | -171 | -200 | -136 | -121 | -112 | -116 | -127 | -111 |
| Working Capital Days | -20 | -65 | -96 | -112 | -74 | -110 | -102 | -26 | -43 | -40 | -70 | -91 |
| ROCE % | 1% | 7% | 6% | 7% | 6% | 3% | 1% | -1% | 5% | 8% | 9% | 9% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Tax Saver Fund | 1,568,743 | 0.47 | 58.11 | 1,568,743 | 2025-04-22 17:25:33 | 0% |
| Tata Mid Cap Growth Fund - Regular Plan | 751,030 | 1.1 | 27.82 | 751,030 | 2025-04-22 17:25:33 | 0% |
| Nippon India Pharma Fund | 400,432 | 0.27 | 14.83 | 400,432 | 2025-04-22 17:25:33 | 0% |
| Taurus Flexi Cap Fund | 68,408 | 0.92 | 2.54 | 68,408 | 2025-04-22 17:25:33 | 0% |
| Motilal Oswal Nifty Microcap 250 Index Fund | 40,049 | 0.32 | 1.48 | 40,049 | 2025-04-22 17:25:33 | 0% |
| ITI Pharma and Healthcare Fund | 31,951 | 0.92 | 1.18 | 31,951 | 2025-04-22 17:25:33 | 0% |
| Tata Equity Savings Fund - Regular Plan - Growth | 26,400 | 0.78 | 0.98 | 26,400 | 2025-04-22 17:25:33 | 0% |
| Taurus ELSS Tax Saver Fund | 20,000 | 1.18 | 0.74 | 20,000 | 2025-04-22 17:25:33 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 399 | 0.18 | 0.01 | 399 | 2025-04-22 17:25:33 | 0% |
| Groww Nifty Total Market Index Fund | 92 | 0.01 | 0 | 92 | 2025-04-22 17:25:33 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 3.19 | 3.46 | 2.11 | 4.14 | -17.02 |
| Diluted EPS (Rs.) | 3.14 | 3.43 | 2.10 | 3.97 | -17.02 |
| Cash EPS (Rs.) | 18.61 | 15.46 | 13.02 | 14.29 | -4.91 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 66.16 | 59.28 | 61.86 | 63.57 | 56.96 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 66.16 | 59.28 | 61.86 | 63.57 | 56.96 |
| Revenue From Operations / Share (Rs.) | 159.44 | 136.97 | 121.58 | 100.55 | 80.84 |
| PBDIT / Share (Rs.) | 30.27 | 24.88 | 22.42 | 18.03 | 11.45 |
| PBIT / Share (Rs.) | 15.12 | 12.36 | 10.67 | 6.64 | -1.25 |
| PBT / Share (Rs.) | 4.03 | 4.83 | 3.23 | 6.42 | -18.21 |
| Net Profit / Share (Rs.) | 3.45 | 2.94 | 1.27 | 2.90 | -17.61 |
| NP After MI And SOA / Share (Rs.) | 3.19 | 3.46 | 2.11 | 3.87 | -15.43 |
| PBDIT Margin (%) | 18.98 | 18.16 | 18.43 | 17.93 | 14.16 |
| PBIT Margin (%) | 9.48 | 9.02 | 8.77 | 6.60 | -1.54 |
| PBT Margin (%) | 2.52 | 3.52 | 2.65 | 6.38 | -22.52 |
| Net Profit Margin (%) | 2.16 | 2.14 | 1.04 | 2.88 | -21.78 |
| NP After MI And SOA Margin (%) | 1.99 | 2.52 | 1.73 | 3.84 | -19.08 |
| Return on Networth / Equity (%) | 4.81 | 5.83 | 3.41 | 6.17 | -27.74 |
| Return on Capital Employeed (%) | 8.44 | 8.76 | 8.50 | 5.27 | -0.99 |
| Return On Assets (%) | 1.25 | 1.77 | 1.26 | 2.42 | -9.50 |
| Long Term Debt / Equity (X) | 0.65 | 0.58 | 0.42 | 0.41 | 0.49 |
| Total Debt / Equity (X) | 1.09 | 0.81 | 0.46 | 0.46 | 0.59 |
| Asset Turnover Ratio (%) | 0.71 | 0.75 | 0.74 | 0.46 | 0.31 |
| Current Ratio (X) | 0.80 | 0.91 | 1.02 | 1.07 | 0.93 |
| Quick Ratio (X) | 0.75 | 0.85 | 0.95 | 1.01 | 0.88 |
| Interest Coverage Ratio (X) | 2.73 | 3.19 | 3.01 | 2.56 | 1.20 |
| Interest Coverage Ratio (Post Tax) (X) | 1.31 | 1.34 | 1.17 | 0.44 | -0.06 |
| Enterprise Value (Cr.) | 8223.62 | 5119.81 | 3866.17 | 3975.48 | 2784.14 |
| EV / Net Operating Revenue (X) | 3.70 | 2.68 | 2.29 | 2.84 | 2.75 |
| EV / EBITDA (X) | 19.48 | 14.77 | 12.40 | 15.86 | 19.40 |
| MarketCap / Net Operating Revenue (X) | 3.37 | 2.47 | 2.16 | 2.68 | 2.36 |
| Price / BV (X) | 8.13 | 5.70 | 4.25 | 4.31 | 3.44 |
| Price / Net Operating Revenue (X) | 3.37 | 2.47 | 2.16 | 2.68 | 2.36 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | -0.08 |
After reviewing the key financial ratios for Healthcare Global Enterprises Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 3.19. This value is below the healthy minimum of 5. It has decreased from 3.46 (Mar 24) to 3.19, marking a decrease of 0.27.
- For Diluted EPS (Rs.), as of Mar 25, the value is 3.14. This value is below the healthy minimum of 5. It has decreased from 3.43 (Mar 24) to 3.14, marking a decrease of 0.29.
- For Cash EPS (Rs.), as of Mar 25, the value is 18.61. This value is within the healthy range. It has increased from 15.46 (Mar 24) to 18.61, marking an increase of 3.15.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 66.16. It has increased from 59.28 (Mar 24) to 66.16, marking an increase of 6.88.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 66.16. It has increased from 59.28 (Mar 24) to 66.16, marking an increase of 6.88.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 159.44. It has increased from 136.97 (Mar 24) to 159.44, marking an increase of 22.47.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 30.27. This value is within the healthy range. It has increased from 24.88 (Mar 24) to 30.27, marking an increase of 5.39.
- For PBIT / Share (Rs.), as of Mar 25, the value is 15.12. This value is within the healthy range. It has increased from 12.36 (Mar 24) to 15.12, marking an increase of 2.76.
- For PBT / Share (Rs.), as of Mar 25, the value is 4.03. This value is within the healthy range. It has decreased from 4.83 (Mar 24) to 4.03, marking a decrease of 0.80.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 3.45. This value is within the healthy range. It has increased from 2.94 (Mar 24) to 3.45, marking an increase of 0.51.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 3.19. This value is within the healthy range. It has decreased from 3.46 (Mar 24) to 3.19, marking a decrease of 0.27.
- For PBDIT Margin (%), as of Mar 25, the value is 18.98. This value is within the healthy range. It has increased from 18.16 (Mar 24) to 18.98, marking an increase of 0.82.
- For PBIT Margin (%), as of Mar 25, the value is 9.48. This value is below the healthy minimum of 10. It has increased from 9.02 (Mar 24) to 9.48, marking an increase of 0.46.
- For PBT Margin (%), as of Mar 25, the value is 2.52. This value is below the healthy minimum of 10. It has decreased from 3.52 (Mar 24) to 2.52, marking a decrease of 1.00.
- For Net Profit Margin (%), as of Mar 25, the value is 2.16. This value is below the healthy minimum of 5. It has increased from 2.14 (Mar 24) to 2.16, marking an increase of 0.02.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.99. This value is below the healthy minimum of 8. It has decreased from 2.52 (Mar 24) to 1.99, marking a decrease of 0.53.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.81. This value is below the healthy minimum of 15. It has decreased from 5.83 (Mar 24) to 4.81, marking a decrease of 1.02.
- For Return on Capital Employeed (%), as of Mar 25, the value is 8.44. This value is below the healthy minimum of 10. It has decreased from 8.76 (Mar 24) to 8.44, marking a decrease of 0.32.
- For Return On Assets (%), as of Mar 25, the value is 1.25. This value is below the healthy minimum of 5. It has decreased from 1.77 (Mar 24) to 1.25, marking a decrease of 0.52.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.65. This value is within the healthy range. It has increased from 0.58 (Mar 24) to 0.65, marking an increase of 0.07.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.09. This value exceeds the healthy maximum of 1. It has increased from 0.81 (Mar 24) to 1.09, marking an increase of 0.28.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.71. It has decreased from 0.75 (Mar 24) to 0.71, marking a decrease of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 0.80. This value is below the healthy minimum of 1.5. It has decreased from 0.91 (Mar 24) to 0.80, marking a decrease of 0.11.
- For Quick Ratio (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 1. It has decreased from 0.85 (Mar 24) to 0.75, marking a decrease of 0.10.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.73. This value is below the healthy minimum of 3. It has decreased from 3.19 (Mar 24) to 2.73, marking a decrease of 0.46.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.31. This value is below the healthy minimum of 3. It has decreased from 1.34 (Mar 24) to 1.31, marking a decrease of 0.03.
- For Enterprise Value (Cr.), as of Mar 25, the value is 8,223.62. It has increased from 5,119.81 (Mar 24) to 8,223.62, marking an increase of 3,103.81.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.70. This value exceeds the healthy maximum of 3. It has increased from 2.68 (Mar 24) to 3.70, marking an increase of 1.02.
- For EV / EBITDA (X), as of Mar 25, the value is 19.48. This value exceeds the healthy maximum of 15. It has increased from 14.77 (Mar 24) to 19.48, marking an increase of 4.71.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.37. This value exceeds the healthy maximum of 3. It has increased from 2.47 (Mar 24) to 3.37, marking an increase of 0.90.
- For Price / BV (X), as of Mar 25, the value is 8.13. This value exceeds the healthy maximum of 3. It has increased from 5.70 (Mar 24) to 8.13, marking an increase of 2.43.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.37. This value exceeds the healthy maximum of 3. It has increased from 2.47 (Mar 24) to 3.37, marking an increase of 0.90.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Healthcare Global Enterprises Ltd:
- Net Profit Margin: 2.16%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.44% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.81% (Industry Average ROE: 14.16%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.31
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.75
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 279 (Industry average Stock P/E: 55.82)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.09
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.16%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | HCG Tower, Bengaluru Karnataka 560027 | investors@hcgel.com https://www.hcgoncology.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. B S Ajai Kumar | Executive Chairman |
| Mr. Raj Gore | WholeTime Director & CEO |
| Ms. Anjali Ajaikumar Rossi | Executive Director |
| Mr. Siddharth Patel | Non Exe.Non Ind.Director |
| Mr. Amit Soni | Non Exe.Non Ind.Director |
| Mr. Rajiv Maliwal | Ind. Non-Executive Director |
| Mr. Jeyandran Venugopal | Ind. Non-Executive Director |
| Mr. Pradip Kanakia | Ind. Non-Executive Director |
| Ms. Geeta Mathur | Ind. Non-Executive Director |
| Mr. Rajagopalan Raghavan | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Healthcare Global Enterprises Ltd?
Healthcare Global Enterprises Ltd's intrinsic value (as of 18 October 2025) is 774.67 which is 5.54% higher the current market price of 734.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 10,350 Cr. market cap, FY2025-2026 high/low of 745/405, reserves of ₹783 Cr, and liabilities of 3,540 Cr.
What is the Market Cap of Healthcare Global Enterprises Ltd?
The Market Cap of Healthcare Global Enterprises Ltd is 10,350 Cr..
What is the current Stock Price of Healthcare Global Enterprises Ltd as on 18 October 2025?
The current stock price of Healthcare Global Enterprises Ltd as on 18 October 2025 is 734.
What is the High / Low of Healthcare Global Enterprises Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Healthcare Global Enterprises Ltd stocks is 745/405.
What is the Stock P/E of Healthcare Global Enterprises Ltd?
The Stock P/E of Healthcare Global Enterprises Ltd is 279.
What is the Book Value of Healthcare Global Enterprises Ltd?
The Book Value of Healthcare Global Enterprises Ltd is 66.2.
What is the Dividend Yield of Healthcare Global Enterprises Ltd?
The Dividend Yield of Healthcare Global Enterprises Ltd is 0.00 %.
What is the ROCE of Healthcare Global Enterprises Ltd?
The ROCE of Healthcare Global Enterprises Ltd is 8.56 %.
What is the ROE of Healthcare Global Enterprises Ltd?
The ROE of Healthcare Global Enterprises Ltd is 5.14 %.
What is the Face Value of Healthcare Global Enterprises Ltd?
The Face Value of Healthcare Global Enterprises Ltd is 10.0.